Filing Flows › Comparisons › LLY vs ABBV
ELI Lilly vs AbbVie: LLY and ABBV compared
ELI Lilly is the larger company: $24.4B of revenue in its latest quarter (Q3 2026) against $17.4B for AbbVie (Q3 2026). ELI Lilly is growing faster (+39% against +10% a year earlier). AbbVie is more profitable, with an operating margin of 36.0% against 34.5%.
Where the money goes: LLY and ABBV
ELI Lilly (LLY) · Q3 2026
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
AbbVie (ABBV) · Q3 2026
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
| ELI Lilly (LLY) | AbbVie (ABBV) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $24.4B | $17.4B |
| Revenue growth, Y/Y | +39% | +10% |
| Operating margin | 34.5% | 36.0% |
| Net earnings | $6.5B | $4.2B |
| Net margin | 26.4% | 24.2% |
| Operating cash flow | $11.4B | $7.6B |
| Free cash flow | $8.2B | $7.3B |
| Market value | $1.22T | $516.2B |
| P/E | 44.3× | 50.1× |
| Analysts’ mean target | $1453.40 | $310.65 |
Where the revenue comes from
ELI Lilly
- Net product revenue: $22.7B (93%)
- Other oncology: $1.1B (4%)
- Other immunology: $579M (2%)
Questions
Which is bigger, ELI Lilly or AbbVie?
ELI Lilly is the larger company: $24.4B of revenue in its latest quarter (Q3 2026) against $17.4B for AbbVie (Q3 2026).
Is ELI Lilly or AbbVie growing faster?
ELI Lilly is growing faster (+39% against +10% a year earlier).
Which is more profitable, ELI Lilly or AbbVie?
AbbVie is more profitable, with an operating margin of 36.0% against 34.5%.
More: ELI Lilly earnings · how ELI Lilly makes money · AbbVie earnings · how AbbVie makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.